We aim to foster a more transparent, collaborative and productive IP/innovation eco-system for India. Retweets are not endorsements.
India
Joined March 2011
- Tweets9.6K
- Following130
- Followers5.8K
- Likes632
Pinned Tweet
As we step into the new year, we thank our readers for their continued support and wish everyone a very happy and healthy year ahead.(5/5)
spicyip.com/2025/12/a-look-b…
SpicyIP Weekly Review (October 12-October 18)
Here’s this week’s roundup of IP developments, from posts on the Kerala High Court’s Ribociclib decision under Section 100 of the Patents Act, the Delhi HC’s tiered approach to patent appeals in Esteve Pharmaceuticals, (1/2)
the PABS Annex of the WHO Pandemic Agreement, to key judicial decisions and national and international IP updates. Anything we missed out on? Drop a comment below to let us know!
spicyip.com/2026/10/spicyip-… (2/2)
Patent research often means working through lengthy judgments to find the reasoning that matters. Prof. Feroz Ali’s newly launched "Ali on Patents" aims to make this process easier, bringing together judicial decisions and doctrinal commentary in a free, online resource. (1/2)
Rishabh Upadhyay takes it for a spin to see how it works in practice and shares his thoughts below:-
spicyip.com/2026/10/spicyip-… (2/2)
In May 2025, WHO member states adopted the Pandemic Agreement, which cannot open for signature until its PABS Annex is finalised. Negotiations remain deadlocked over whether benefit sharing should be tied to pathogen data access. (1/2)
In this post, Rishabh Upadhyay examines the EU’s Hybrid Model, the African Group’s Federated Model, and KEI’s proposal to delink the two, arguing that KEI’s approach offers a more robust solution but requires one key fix.
spicyip.com/2026/10/equitabl… (2/2)
The Centre for Intellectual Property Rights (CIPR), Institute of Law, Nirma University is inviting submissions for the Journal of Intellectual Property Laws(JIPL), Volume X. The last date for submission is 30 November. (1/2)
For more details, read the call for submissions below :-
spicyip.com/2026/10/call-for… (2/2)
As Halloween approaches, a particular editorial at ET seems spooked by the prospect of lawful and equitable access to medicines! In doing the opposite of what its title suggests, ‘Protect Patients and Patents Smartly’, the editorial piece published on October 15, 2026 (1/3)
is an unfortunate example of legal misinformation and misinterpretation, stuck in the old binary of access versus patent. Ambika Aggarwal explains how this published piece runs contrary to years of judicial wisdom, contradicts itself, conflates different legal questions.. (2/3)
...and advocates for a rather shocking political consequence.
spicyip.com/2026/10/the-ghos… (3/3)
In Esteve Pharmaceuticals, the Delhi High Court found that a patent application lacked inventive step and declined to examine whether it also fell foul of the exclusions under Sections 3(d) and 3(e) of the Patents Act, invoking judicial economy. (1/2)
But does this approach get the sequence of patentability assessment right? Maneesha Gupta takes a closer look at the statutory scheme and examination guidelines and raises questions about whether the Court has put the cart before the horse.
spicyip.com/2026/10/putting-… (2/2)
What happens when public money helps make an innovation possible, but the public has little say in who gets to benefit from it? This week’s Bell of the Week looks at economist @MazzucatoM work on public investment, innovation, and how its rewards are shared. (1/3)
Her work offers an interesting way to think about a question at the heart of IP: when the public helps fund innovation, how much of its benefits should return to the public? (2/3)
Read this week’s Bells & Whistles by Gaurangi Kapoor to find out why this is a question worth asking.
spicyip.com/2026/10/spicyip-… (3/3)
SpicyIP Weekly Review (October 5-October 11)
From notable orders of the past week to key national and international IP developments, here’s the latest edition of the SpicyIP Weekly Review. Did we miss anything? Let us know in the comments!
spicyip.com/2026/10/spicyip-…
Ribociclib could become the highest-selling drug in Novartis’ history, yet access to this life-saving medicine remains a pressing concern for patients who cannot afford it. The Kerala High Court’s recent ruling on government use of patented inventions under Section 100...(1/3)
raises questions about the data needed to invoke this provision and the role of government policy in enabling access. Ambika Aggarwal and Rishabh Upadhyay examine the ruling as a missed opportunity for a public-health-centric approach, situating it alongside...(2/3)
...other Ribociclib patent disputes and potential changes to patent enforcement and drug pricing rules. (3/3)
spicyip.com/2026/10/ribocicl…
